Ottawa, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The global viral vector and plasmid DNA manufacturing market size was valued at USD 7.19 billion in 2024 and is expected to be worth around USD 46.02 billion ...
Aldevron, a Danaher company and global leader in the production of DNA, RNA and protein for genomic medicine, and Minaris, a global cell and gene therapy contract development and manufacturing ...
AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® ...
The use of performance-enhancing drugs in sports is commonly referred by the term ‘doping’, particularly by those regulatory bodies overseeing sports that have made efforts to fight doping. Through ...
Throughout this three-part webinar series, experts from USP and industry will share first-hand experiences, case studies, and ...
ROCKVILLE, Md. May 8, 2026 /PRNewswire=YONHAP/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and ...
Gene therapy using transiently expressed non-integrative plasmid vectors is the ideal solution for many public health applications. For example, no current therapy for diabetic foot ulcers directly ...
The Viral Vector and Plasmid DNA Manufacturing Market refers to the industrial processes and services that enable the production of viral vectors and plasmid DNA used in gene therapies, vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results